Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.40 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752142 | 1.00 | CTSL (0.48) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL12657499 | 1.00 | CTSL (0.48) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL18206273 | 0.92 | CTSL (0.44) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL18206276 | 0.92 | CTSL (0.44) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL18206277 | 0.92 | CTSL (0.44) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL23771861 | 0.89 | CTSL (0.40) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL18916653 | 0.88 | CTSK (0.42) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL18762624 | 0.88 | CTSS (0.37) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL10347068 | 0.87 | CYP1A2 (0.38) | CTSLCTSKCTSBCTSSCA1 | |
| SCHEMBL22199794 | 0.87 | CTSK (0.46) | CTSLCTSKCTSBCTSSCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117186176-A | Tengtoxin hapten, antigen, antibody, detection device and preparation and application thereof | 广东科贸职业学院 | 2023-12-08 | — | — | CN | claimed |
| US-6306203-B1 | FOR USE IN INK JET PRINTING, INCLUDING PIEZOELECTRIC INK JET PRINTING AND ACOUSTIC INK JET PRINTING | XEROX CORPORATION | 2001-10-23 | — | — | US | claimed |
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2026-04-28 | — | — | US | disclosed |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250320233-A1 | ARGINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2025-10-16 | — | — | US | disclosed |
| WO-2025108986-A1 | 2-AMINO-N-(OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2025-05-30 | — | — | WO | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| US-20250122153-A1 | Protease Inhibitors as Antivirals | ACEA Therapeutics, Inc. (US) | 2025-04-17 | — | — | US | disclosed |
| EP-0169812-B1 | PHOSPHATIDYL COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1989-08-23 | — | — | EP | disclosed |
| US-4788182-A | VIRICIDES | CIBA-GEIGY CORPORATION (US) | 1988-11-29 | — | — | US | disclosed |
| EP-0186977-A2 | Renin-inhibitory dipeptides, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1986-07-09 | — | — | EP | disclosed |
| EP-0169812-A1 | Phosphatidyl compounds, process for their preparation and their use | CIBA-GEIGY AG (CH) | 1986-01-29 | — | — | EP | disclosed |
| EP-0000063-B1 | DIPEPTIDE DERIVATIVES OF 7-(N-ALPHA-SUBSTITUTED OR NON-SUBSTITUTED X-ARGINYL)-AMINO-4-METHYL-COUMARIN | AJINOMOTO CO., INC. (JP) | 1981-06-10 | — | — | EP | disclosed |
| US-4257939-A | SUBSTRATES FOR DETERMINING ENZYME ACTIVITY | AJINOMOTO CO., INC. (JP) | 1981-03-24 | — | — | US | disclosed |
| US-4237047-A | FLUORESCENT SUBSTRATE FOR MEASURING ENZYME ACTIVITY | AJINOMOTO COMPANY, INCORPORATED (JP) | 1980-12-02 | — | — | US | disclosed |
| US-4215047-A | FLUOROGENIC SUBSTRATES FOR DETERMINING ENZYMATIC ACTIVITIES | AJINOMOTO COMPANY INCORPORATED (JP) | 1980-07-29 | — | — | US | disclosed |
| US-4064270-A | ANTHELMINTICS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | CTSL 145/4885CTSK 1499/4885CTSB 1236/4885 |
| US-20250122153-A1 | Protease Inhibitors as Antivirals | ACE, ACE2, TMPRSS15 | CTSL 4/4885CTSK 86/4885CTSB 44/4885 |
| US-20250320233-A1 | ARGINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ARG1, ARG2, PRMT1 | CTSL 1464/4885CTSK 1677/4885CTSB 1102/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | CTSL 164/4885CTSK 1659/4885CTSB 1425/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSL 12/4885CTSK 586/4885CTSB 508/4885 |
| US-12295942-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSL 12/4885CTSK 586/4885CTSB 508/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CTSL 12/4885CTSK 586/4885CTSB 508/4885 |
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | ARG1, ARG2, ARGLU1 | CTSL 101/4885CTSK 1074/4885CTSB 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.